# Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

> **NCT00038883** · NA · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic
- Leukemia, Lymphocytic, Acute
- Lymphoma, Low-Grade
- Lymphoma, T-Cell
- Lymphoma, B-Cell

## Interventions

- **DRUG:** Campath-1H

## Key facts

- **NCT ID:** NCT00038883
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-04-09
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038883, "Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00038883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*